Skip to content
‹ Back to IndustriesHealthcare

Are Blood Plasma Treatments Due for a Revolution?

Dr Trevor Castor is the President of Aphios International, a name that means “virus-free” in Greek. “We are developing a pathogen-reduction technology called CFI to clear blood plasma, plasma products, biologics and medical devices of viruses and other pathogens. Our technology is unique in that it does not use heat, chemicals or radiation that could be harmful…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Dr Trevor Castor is the President of Aphios International, a name that means “virus-free” in Greek.

“We are developing a pathogen-reduction technology called CFI to clear blood plasma, plasma products, biologics and medical devices of viruses and other pathogens.

Our technology is unique in that it does not use heat, chemicals or radiation that could be harmful to the underlying beneficial proteins, such as antibodies.

Our technology works by giving the virus the bends. [We put] virus particles with a gas under pressure, then quickly release the pressure, and the infected virus pops at the weakest points, very much like the disruption of a scuba diver who rises too rapidly or the popping of a balloon.

Our research, funded by the National Institutes of Health, has been successful, and we are [continually] raising funds.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal says health systems need a measured baseline, clinician-led workflow design and representative data before they scale. Small pilots hide the rest.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition, which baseline metric and what projected cost at full volume will this tool be judged against?

Nov 18, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512